Spojené státy - angličtina - NLM (National Library of Medicine)

la jolla pharmaceutical company - angiotensin ii (unii: m089efu921) (angiotensin ii - unii:m089efu921) - angiotensin ii 2.5 mg in 1 ml - giapreza increases blood pressure in adults with septic or other distributive shock [see clinical studies (14)] . none. risk summary the published data on angiotensin ii use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. animal reproduction studies have not been conducted with giapreza. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk septic or other distributive shock is a medical emergency that can be fatal if left untreated. delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to incr

Evropská unie - angličtina - EMA (European Medicines Agency)

paion deutschland gmbh - angiotensin ii acetate - hypotension; shock - agents acting on the renin-angiotensin system - giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Evropská unie - angličtina - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - eprosartan mesylate - film-coated tablet - 300 milligram(s) - angiotensin ii antagonists, plain; eprosartan - angiotensin ii antagonists, plain. - it is indicated in adults for the treatment of essential hypertension.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - eprosartan mesylate - film-coated tablet - 400 milligram(s) - angiotensin ii antagonists, plain; eprosartan - angiotensin ii antagonists, plain. - it is indicated in adults for the treatment of essential hypertension.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - eprosartan mesylate - film-coated tablet - 600 milligram(s) - angiotensin ii antagonists, plain; eprosartan - angiotensin ii antagonists, plain. - it is indicated in adults for the treatment of essential hypertension.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

bgp products ltd - eprosartan mesylate - film coated tablet - 400 milligram - angiotensin ii antagonists, plain - angiotensin-ii antagonists, plain c - eprosartan is indicated for the treatment of essential hypertension.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

bgp products ltd - eprosartan mesylate - film coated tablet - 600 milligram - angiotensin ii antagonists, plain - angiotensin-ii antagonists, plain c - eprosartan is indicated for the treatment of essential hypertension

Evropská unie - angličtina - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Evropská unie - angličtina - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension